Sacubitril/valsartan for heart failure with reduced left ventricular ejection fraction : A retrospective cohort study.
CONCLUSION: Sacubitril/valsartan offered strong protection against all-cause death and HF hospitalizations at 6 months without any significant side effects. To validate this efficacious molecule, further postmarketing observational studies, focusing mainly on hypotension and angioedema are warranted.
PMID: 29350254 [PubMed - as supplied by publisher]
Source: Herz - Category: Cardiology Tags: Herz Source Type: research
More News: Beta-Blockers | Cardiology | Cardiovascular | Diovan | Enalapril | Furosemide | Heart | Heart Failure | Study